Publication:
Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles

0
0

Issued Date

2014

Resource Type

Article

File Type

application/pdf

ISSN

9396411

DOI

10.1016/j.ejpb.2014.06.020

Other identifier(s)

2-s2.0-84908373348

Rights Holder(s)

มหาวิทยาลัยศรีนครินทรวิโรฒ

Bibliographic Citation

European Journal of Pharmaceutics and Biopharmaceutics. Vol 88, No.2 (2014), p.529-538

Suggested Citation

Chittasupho C., Lirdprapamongkol K., Kewsuwan P., Sarisuta N. Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics. Vol 88, No.2 (2014), p.529-538. doi:10.1016/j.ejpb.2014.06.020 Retrieved from: https://hdl.handle.net/20.500.14740/6439

Title

Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles

Author(s)

Chittasupho C.
 Lirdprapamongkol K.
 Kewsuwan P.
 Sarisuta N.

Abstract

Doxorubicin is used to treat a variety of cancers, but dose limiting toxicity or intrinsic and acquired resistance limits its application in many types of cancer. CXCR4 is a chemokine receptor which implicates in metastasis of cancers including lung cancer. LFC131, a peptide inhibitor of CXCR4-ligand binding, is a linear type of low molecular weight CXCR4 antagonist. In this study, we investigated the possibility of using LFC131 conjugated nanoparticles for targeted delivering doxorubicin to CXCR4 expressing lung cancer cells. The LFC131 peptide was conjugated to sodium carboxylmethyl cellulose coated poly(dl-lactic-co-glycolic acid) (PLGA) nanoparticles. Binding and cellular uptake of doxorubicin-loaded LFC131 conjugated nanoparticles (LFC131-DOX NP) in adenocarcinomic human alveolar basal epithelial cells called A549 cells were higher and faster than that of untargeted nanoparticles. The specificity of CXCR4-mediated internalization of LFC131-DOX NPs was confirmed by using free LFC131 peptide or anti-CXCR4 monoclonal antibody. Cell studies suggested that sustained release of doxorubicin afforded by PLGA nanoparticles may enable LFC131-DOX NP as a targeted and controlled release drug delivery system. © 2014 Elsevier B.V. All rights reserved.

Subject(s)

Chemokine receptor CXCR4
 Chemokine receptor CXCR4 antagonist
 Doxorubicin
 Polyglactin
 Antineoplastic antibiotic
 Chemokine receptor CXCR4
 CXCR4 protein, human
 Doxorubicin
 Lactic acid
 Nanoparticle
 Polyglycolic acid
 Polylactic acid-polyglycolic acid copolymer
 A549 cell line
 Article
 Binding affinity
 Cancer cell
 Cell viability
 Controlled drug release
 Controlled study
 Drug conjugation
 Drug delivery system
 Fluorescence microscopy
 Fluorescence spectroscopy
 Human
 Human cell
 In vitro study
 Light scattering
 Lung cancer
 Nanoencapsulation
 Particle size
 Protein expression
 Reversed phase high performance liquid chromatography
 Sustained drug release
 Zeta potential
 Antagonists and inhibitors
 Chemistry
 Lung tumor
 Metabolism
 Pathology
 Tumor cell line
 Antibiotics, Antineoplastic
 Cell Line, Tumor
 Doxorubicin
 Humans
 Lactic Acid
 Lung Neoplasms
 Microscopy, Fluorescence
 Nanoparticles
 Polyglycolic Acid
 Receptors, CXCR4

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/6439

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By